Preventing heart damage from breast cancer chemotherapy with two diabetes drugs
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether two different diabetes drugs (SGLT-2 inhibitors and DPP-4 inhibitors) can help prevent heart damage that anthracycline chemotherapy can cause in breast cancer patients. You would receive one of the two drugs during your treatment to see if it protects your heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- You must have a breast cancer diagnosis and be scheduled to receive a type of chemotherapy called an anthracycline (like doxorubicin or epirubicin).
- Your heart function must be normal, as confirmed by an echocardiogram.
- You must not have diabetes or a history of diabetic ketoacidosis.
- You must not have other serious heart problems, or significant kidney or liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks how well the heart handles anthracycline chemotherapy in breast cancer patients. It helps doctors find early signs of heart side effects so they can keep you safe during treatment.
This trial tests whether a daily pill called dapagliflozin can help protect the heart from damage caused by doxorubicin chemotherapy in people being treated for early-stage breast cancer. If you are starting doxorubicin and have a healthy heart, this might lower your risk of heart problems later.
This trial tests if the diabetes drug dapagliflozin can protect the heart in people with breast cancer receiving a type of chemotherapy called anthracyclines. You may be able to join if you are between 18 and 80, have stage I-III breast cancer, and are about to start anthracycline treatment within the next 60 days.
This trial tests if a heart-protecting drug called dapagliflozin can help prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. It may be an option if you have low to medium heart risk factors.
This trial tests if the drug dapagliflozin can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. It aims to see if taking the drug during chemo helps keep your heart healthy.
This trial tests if a diabetes medicine called dapagliflozin (also known as Farxiga) can protect the hearts of women with breast cancer while they receive anthracycline chemotherapy. You would take the medicine and have heart MRI scans to see if it helps prevent heart damage.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.